FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885646768> ?p ?o ?g. }

• W2885646768 endingPage "PR02" @default.
• W2885646768 startingPage "PR02" @default.
• W2885646768 abstract "Abstract PARP inhibitors (PARPi) have improved the outcomes of patients with high-grade serous ovarian carcinomas (HGSOC) whose tumors harbor mutations in homologous recombination genes such BRCA1 and BRCA2. However, only 20% of cases with this aggressive subtype of ovarian cancer benefit from PARPi, thus highlighting the essential need to identify novel therapeutic strategies for the remainder of these patients. We have recently reported that off-target effects vary among two PARP inhibitors with different trapping potencies. The FDA-approved PARPi, Olaparib, activated the checkpoint kinase 1 (CHK1) protein at serine 345 and arrested cells in the G2/M phase; however, these effects were not observed after treatment with Veliparib, the least potent PARPi measured by the PARP trapping ability. In this study, we treated HGSOC cell lines with the five most clinically advanced PARP inhibitors and investigated the effect of varying PARP trapping potencies on the expression levels of major proteins that are involved in cell cycle pathways via Western blot and cell cycle analysis. The synergy between the most potent (Talazoparib) or least potent PARP trappers and a CHK1 inhibitor was also explored in HGSOC patient-derived xenograft (PDX) models. We hypothesize that PARP inhibitors that do not have an effect on the cell cycle will have greater synergy with CHK1 inhibitors. Our results reveal that the four most potent PARP trappers—olaparib, rucaparib, niraparib, and talazoparib--activate CHK1 protein and decrease total protein levels of CHK1’s downstream substrate CDC25C. However, we did not observe any significant changes in expression levels in these two proteins after treatment with veliparib. We also observed an arrest in the S/G2 phase of the cell cycle after treatment with the four most potent PARP inhibitors. Finally, the growth of our PDX model was significantly inhibited by combined treatment with veliparib and the CHK1 inhibitor MK-8776 compared to either single-agent therapy or talazoparib combined with MK-8776. These results suggest that there is a distinct off-target effect that differs among the least and most potent PARP inhibitors, with veliparib being more synergistic with CHK1 inhibition. This study will help to expand the use of PARP inhibitors in combination with CHK1 inhibitors and emphasizes the importance of single-agent off-target effects to develop optimal combination therapies. This abstract is also being presented as Poster A11. Citation Format: Monicka Wielgos-Bonvallet, Paulina Cybulska, Elke Van Oudenhove, Petar Jelinic, Douglas A. Levine. Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr PR02." @default.
• W2885646768 created "2018-08-22" @default.
• W2885646768 creator A5005570865 @default.
• W2885646768 creator A5008988636 @default.
• W2885646768 creator A5019282569 @default.
• W2885646768 creator A5036444245 @default.
• W2885646768 creator A5044975619 @default.
• W2885646768 date "2018-08-01" @default.
• W2885646768 modified "2023-09-23" @default.
• W2885646768 title "Abstract PR02: Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition" @default.
• W2885646768 doi "https://doi.org/10.1158/1557-3265.ovca17-pr02" @default.
• W2885646768 hasPublicationYear "2018" @default.
• W2885646768 type Work @default.
• W2885646768 sameAs 2885646768 @default.
• W2885646768 citedByCount "1" @default.
• W2885646768 countsByYear W28856467682019 @default.
• W2885646768 crossrefType "journal-article" @default.
• W2885646768 hasAuthorship W2885646768A5005570865 @default.
• W2885646768 hasAuthorship W2885646768A5008988636 @default.
• W2885646768 hasAuthorship W2885646768A5019282569 @default.
• W2885646768 hasAuthorship W2885646768A5036444245 @default.
• W2885646768 hasAuthorship W2885646768A5044975619 @default.
• W2885646768 hasConcept C105696609 @default.
• W2885646768 hasConcept C121608353 @default.
• W2885646768 hasConcept C126322002 @default.
• W2885646768 hasConcept C182979987 @default.
• W2885646768 hasConcept C2779138821 @default.
• W2885646768 hasConcept C2779962180 @default.
• W2885646768 hasConcept C2781312401 @default.
• W2885646768 hasConcept C29537977 @default.
• W2885646768 hasConcept C50001416 @default.
• W2885646768 hasConcept C502942594 @default.
• W2885646768 hasConcept C54355233 @default.
• W2885646768 hasConcept C552990157 @default.
• W2885646768 hasConcept C71924100 @default.
• W2885646768 hasConcept C82381507 @default.
• W2885646768 hasConcept C86803240 @default.
• W2885646768 hasConceptScore W2885646768C105696609 @default.
• W2885646768 hasConceptScore W2885646768C121608353 @default.
• W2885646768 hasConceptScore W2885646768C126322002 @default.
• W2885646768 hasConceptScore W2885646768C182979987 @default.
• W2885646768 hasConceptScore W2885646768C2779138821 @default.
• W2885646768 hasConceptScore W2885646768C2779962180 @default.
• W2885646768 hasConceptScore W2885646768C2781312401 @default.
• W2885646768 hasConceptScore W2885646768C29537977 @default.
• W2885646768 hasConceptScore W2885646768C50001416 @default.
• W2885646768 hasConceptScore W2885646768C502942594 @default.
• W2885646768 hasConceptScore W2885646768C54355233 @default.
• W2885646768 hasConceptScore W2885646768C552990157 @default.
• W2885646768 hasConceptScore W2885646768C71924100 @default.
• W2885646768 hasConceptScore W2885646768C82381507 @default.
• W2885646768 hasConceptScore W2885646768C86803240 @default.
• W2885646768 hasIssue "15_Supplement" @default.
• W2885646768 hasLocation W28856467681 @default.
• W2885646768 hasOpenAccess W2885646768 @default.
• W2885646768 hasPrimaryLocation W28856467681 @default.
• W2885646768 hasRelatedWork W2001870355 @default.
• W2885646768 hasRelatedWork W2086824644 @default.
• W2885646768 hasRelatedWork W2139802796 @default.
• W2885646768 hasRelatedWork W2300265398 @default.
• W2885646768 hasRelatedWork W2403598358 @default.
• W2885646768 hasRelatedWork W2808701886 @default.
• W2885646768 hasRelatedWork W2885646768 @default.
• W2885646768 hasRelatedWork W3187134068 @default.
• W2885646768 hasRelatedWork W4281781196 @default.
• W2885646768 hasRelatedWork W4312194917 @default.
• W2885646768 hasVolume "24" @default.
• W2885646768 isParatext "false" @default.
• W2885646768 isRetracted "false" @default.
• W2885646768 magId "2885646768" @default.
• W2885646768 workType "article" @default.